Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Accenture
McKinsey
Colorcon
Express Scripts
Boehringer Ingelheim
QuintilesIMS
Johnson and Johnson
Farmers Insurance
Queensland Health

Generated: October 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
Abstract: This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
Inventor(s): Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT)
Assignee: Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:14/080,457
Patent Claims:1. A method of inhibiting an immune response in a subject who has received or will receive a cell, tissue, or organ transplant, wherein said method comprises administering to the subject an effective amount of i) an agent which inhibits interaction between CD200 and CD200R and ii) an immunosuppressive .[.or.]. drug, wherein the agent is an anti-CD200 antibody, or antigen-binding fragment thereof, exhibiting reduced effector function.

2. The method of claim 1, wherein said immune response is a humoral response.

3. The method of claim 2, wherein said immune response is an antibody mediated response.

4. The method of claim 2, wherein said agent has no effector function.

5. The method of claim 1, wherein said immunosuppressive drug is cyclosporine A or rapamycin.

6. The method of claim 1, wherein said anti-CD200 antibody, or antigen-binding fragment thereof, is selected from the group consisting of: a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a primatized antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, and a de-immunized antibody or antigen-binding fragment thereof.

7. The method of claim 1, wherein said antigen-binding fragment is selected from the group consisting of: single-chain antibody, Fab, Fab', F(ab').sub.2, F(ab').sub.3, Fd, Fv, domain antibody, and any fragment of an anti-CD200 immunoglobulin that confers specific binding to CD200.

8. The method of claim 1, wherein said immunosuppressive drug is a calcineurin inhibitor.

9. The method of claim 8, wherein said calcineurin inhibitor is selected from the group consisting of tacrolimus and cyclosporine A.

10. The method of claim 1, wherein said immunosuppressive drug is selected from the group consisting of: adriamycin, azathiopurine, busulfan, cyclophosphamide, cyclosporine A, fludarabine, 5- fluorouracil, methotrexate, mycophenolate mofetil, a nonsteroidal anti-inflammatory, sirolimus (rapamycin), and tacrolimus (FK-506).

11. The method of claim 1, wherein said immunosuppressive drug is an antibody selected from the group consisting of: muromonab-CD3, alemtuzumab, basiliximab, daclizumab, rituximab, and anti-thymocyte globulin.

12. The method of claim 1, wherein said subject is human.

13. The method of claim 1, wherein said method prevents graft rejection or promotes graft survival.

14. The method of claim 1, wherein said method comprises administering to said subject said agent and said drug prior to receiving said .[.allograft.]. .Iadd.cell, tissue or organ transplant.Iaddend..

15. The method of claim 1, wherein said agent is administered i) prior to said drug, ii) subsequently to said drug, or iii) simultaneously with said drug.

16. The method of claim 1, wherein said method comprises administering said agent during a rejection episode of said .[.allograft.]. .Iadd.cell, tissue or organ transplant.Iaddend..

17. The method of claim 13, wherein said graft rejection is an acute or a chronic humoral rejection of a grafted cell, tissue, or organ.

18. The method of claim 1, wherein said subject is a recipient of a hematopoietic cell or bone marrow transplant, an allogeneic transplant of pancreatic islet cells, or a solid organ transplant selected from the group consisting of: a heart, a kidney-pancreas, a kidney, a liver, a lung, and a pancreas.

19. The method of claim 1, wherein said method results in a decrease in the production of anti-donor antibodies.

20. The method of claim 13, wherein said graft rejection is an acute graft rejection in a graft recipient of cell, tissue or organ allo- or xenotransplant.

21. The method of claim 13, wherein said graft rejection is a chronic graft rejection in a graft recipient of cell, tissue or organ allo- or xenotransplant.

22. The method of claim 1, wherein said method promotes long-term graft survival, wherein said long-term graft survival is selected from the group consisting of: (a) at least 6 months post transplant; (b) at least 1 year post transplant; and (c) at least 5 years post transplant.

23. The method of claim 22, wherein said method promotes accommodation of the graft.

24. The method of claim 1, wherein said agent is administered systemically.

25. The method of claim 1, wherein said agent is administered locally.

26. The method of claim 1, wherein said immune response is a primary response.

27. The method of claim 1, wherein said immune response is a secondary response.

28. A method of decreasing what constitutes an effective amount of an immunosuppressive .[.or.]. drug administered to a subject who has received or will receive an allograft, said method comprising administering to said subject i) said immunosuppressive .[.or immunomodulatory.]. drug and ii) an anti-CD200 antibody or antigen-binding fragment thereof which inhibits interaction between CD200 and CD200R and exhibits reduced effector function, wherein less of said drug is required to effect immunosuppression .[.or immunomodulation.]. as compared to administering said drug without said anti-CD200 antibody or antigen-binding fragment thereof.

29. The method of claim 28 wherein said drug is cyclosporine A or rapamycin.

30. A method of inhibiting rejection of an allograft in an allograft recipient during a rejection episode, said method comprising administering to said allograft recipient an effective amount of an anti-CD200 antibody or antigen-binding fragment thereof which inhibits interaction between CD200 and CD200R and exhibits reduced effector function, wherein rejection of said allograft is inhibited.

.Iadd.31. The method of claim 1, wherein said cell, tissue or organ transplant is an allograft. .Iaddend.

.Iadd.32. The method of claim 1, wherein said anti-CD200 antibody or antigen-binding fragment thereof exhibits: (a) no ADCC activity, (b) no CDC activity, or (c) no ADCC activity and no CDC activity. .Iaddend.

.Iadd.33. The method of claim 1, wherein said anti-CD200 antibody comprises a variant Fc region derived from an IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgA, IgD, or IgE antibody. .Iaddend.

.Iadd.34. The method of claim 1, wherein said anti-CD200 antibody comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28. .Iaddend.

.Iadd.35. The method of claim 28, wherein said anti-CD200 antibody or antigen-binding fragment thereof exhibits: (a) no ADCC activity, (b) no CDC activity, or (c) no ADCC activity and no CDC activity. .Iaddend.

.Iadd.36. The method of claim 28, wherein said anti-CD200 antibody comprises a variant Fc region derived from an IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgA, IgD, or IgE antibody. .Iaddend.

.Iadd.37. The method of claim 28, wherein said anti-CD200 antibody comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28. .Iaddend.

.Iadd.38. The method of claim 30, wherein said anti-CD200 antibody or antigen-binding fragment thereof exhibits: (a) no ADCC activity, (b) no CDC activity, or (c) no ADCC activity and no CDC activity. .Iaddend.

.Iadd.39. The method of claim 30, wherein said anti-CD200 antibody comprises a variant Fc region derived from an IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgA, IgD, or IgE antibody. .Iaddend.

.Iadd.40. The method of claim 30, wherein said anti-CD200 antibody comprises a variant Fc constant region that has ADCC activity or CDC activity equal to or less than the ADCC activity or CDC activity the antibody would have if it had a Fc constant region comprising: (a) a glutamic acid substitution at amino acid position 236, (b) a glutamine substitution at amino acid position 298, and (c) an alanine substitution at amino acid positions 319, 321, and 323, wherein each substitution is relative to the amino acid sequence depicted in SEQ ID NO:28. .Iaddend.

Summary for Patent: ► Subscribe

PCT Information
PCT FiledJuly 25, 2008PCT Application Number:PCT/US2008/009037
PCT Publication Date:January 29, 2009PCT Publication Number: WO2009/014745

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXsearch
Novartis
SIMULECT
basiliximab
VIAL; SINGLE-USE1037640011998-05-12► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXsearch
Novartis
SIMULECT
basiliximab
VIAL; SINGLE-USE1037640021998-05-12► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXsearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480012001-05-07► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480022001-05-07► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXOrphansearch
Genzyme
LEMTRADA
alemtuzumab
INJECTABLE;INJECTION1039480032001-05-07► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXOrphansearch
Biogen
ZINBRYTA
daclizumab
INJECTABLE;INJECTION7610290012016-05-27► Subscribe Alexion Pharmaceuticals, Inc. (New Haven, CT) Rother; Russell P. (Oklahoma City, OK), Faas McKnight; Susan (Old Lyme, CT) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
AstraZeneca
Medtronic
Julphar
Cantor Fitzgerald
Federal Trade Commission
Express Scripts
Novartis
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot